Skip to main content
Top
Published in: Tumor Biology 11/2016

Open Access 01-11-2016 | Original Article

Hepatitis C virus promotes hepatocellular carcinogenesis by targeting TIPE2, a new regulator of DNA damage response

Authors: Yaohui Wang, Yinan Jiang, Jinxue Zhou, Wuhui Song, Jing Li, Mingli Wang, Jiuge Chen, Rui Xu, Jingjing Zhang, Fanni Ma, Youhai H. Chen, Yuanfang Ma

Published in: Tumor Biology | Issue 11/2016

Login to get access

Abstract

Infection of hepatitis C virus (HCV) is associated with primary hepatocellular carcinoma (HCC). However, its underlying molecular mechanisms remain enigmatic. Tumor necrosis factor-α-induced protein 8-like 2 (TIPE2), a new negative regulator of immunity, plays significant roles in modulating inflammation and tumorigenesis. We hypothesized that TIPE2 might be involved in the development of HCV-induced HCC. To test this hypothesis, the expression of TIPE2 was determined by Western blot in the tumor and pericarcinomatous tissues collected from ten HCV-positive HCC patients; the interaction between TIPE2 and HCV-encoded non-structural proteins was analyzed by immunoprecipitation and immunofluorescence assays, and tumorigenesis and its mechanisms were studied in cell models and nude mice. Our results demonstrated that the expression of TIPE2 was significantly reduced in HCC tissues compared to that in the paracarcinoma tissues. HCV-encoded non-structural protein NS5A could specifically interact with TIPE2 and induce its degradation. Downregulation of TIPE2 by shRNA in cell lines increased genomic DNA damage and promoted cell colony formation in vitro and tumorigenesis in nude mice. In contrast, overexpression of TIPE2 had an opposite effect. Downregulation of TIPE2 by NS5A is associated with genomic DNA instability and HCV-induced HCC development. Thus, TIPE2 may be a new therapeutic target for the treatment of HCV-associated HCC.
Literature
1.
2.
go back to reference Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28:753–70.CrossRefPubMed Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28:753–70.CrossRefPubMed
3.
go back to reference Fan JH, Wang JB, Jiang Y, Xiang W, Liang H, et al. Attributable causes of liver cancer mortality and incidence in China. Asian Pac J Cancer Prev. 2013;14:7251–6.CrossRefPubMed Fan JH, Wang JB, Jiang Y, Xiang W, Liang H, et al. Attributable causes of liver cancer mortality and incidence in China. Asian Pac J Cancer Prev. 2013;14:7251–6.CrossRefPubMed
4.
5.
go back to reference Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, et al. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest. 2008;118:683–94.PubMedPubMedCentral Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, et al. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest. 2008;118:683–94.PubMedPubMedCentral
6.
go back to reference Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065–7.CrossRefPubMed Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065–7.CrossRefPubMed
7.
go back to reference Machida K, Tsukamoto H, Liu JC, Han YP, Govindarajan S, et al. c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair. Hepatology. 2010;52:480–92.CrossRefPubMedPubMedCentral Machida K, Tsukamoto H, Liu JC, Han YP, Govindarajan S, et al. c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair. Hepatology. 2010;52:480–92.CrossRefPubMedPubMedCentral
8.
go back to reference Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol. 1995;69:3893–6.PubMedPubMedCentral Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol. 1995;69:3893–6.PubMedPubMedCentral
9.
go back to reference Machida K, Cheng KT, Lai CK, Jeng KS, Sung VM, et al. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J Virol. 2006;80:7199–207.CrossRefPubMedPubMedCentral Machida K, Cheng KT, Lai CK, Jeng KS, Sung VM, et al. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J Virol. 2006;80:7199–207.CrossRefPubMedPubMedCentral
10.
go back to reference Baek KH, Park HY, Kang CM, Kim SJ, Jeong SJ, et al. Overexpression of hepatitis C virus NS5A protein induces chromosome instability via mitotic cell cycle dysregulation. J Mol Biol. 2006;359:22–34.CrossRefPubMed Baek KH, Park HY, Kang CM, Kim SJ, Jeong SJ, et al. Overexpression of hepatitis C virus NS5A protein induces chromosome instability via mitotic cell cycle dysregulation. J Mol Biol. 2006;359:22–34.CrossRefPubMed
11.
go back to reference Lai CK, Jeng KS, Machida K, Cheng YS, Lai MM. Hepatitis C virus NS3/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiation. Virology. 2008;370:295–309.CrossRefPubMed Lai CK, Jeng KS, Machida K, Cheng YS, Lai MM. Hepatitis C virus NS3/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiation. Virology. 2008;370:295–309.CrossRefPubMed
12.
go back to reference Machida K, McNamara G, Cheng KT, Huang J, Wang CH, et al. Hepatitis C virus inhibits DNA damage repair through reactive oxygen and nitrogen species and by interfering with the ATM-NBS1/Mre11/Rad50 DNA repair pathway in monocytes and hepatocytes. J Immunol. 2010;185:6985–98.CrossRefPubMedPubMedCentral Machida K, McNamara G, Cheng KT, Huang J, Wang CH, et al. Hepatitis C virus inhibits DNA damage repair through reactive oxygen and nitrogen species and by interfering with the ATM-NBS1/Mre11/Rad50 DNA repair pathway in monocytes and hepatocytes. J Immunol. 2010;185:6985–98.CrossRefPubMedPubMedCentral
13.
go back to reference Wang Y, Wang Y, Xu Y, Tong W, Pan T, et al. Hepatitis C virus NS5B protein delays s phase progression in human hepatocyte-derived cells by relocalizing cyclin-dependent kinase 2-interacting protein (CINP). J Biol Chem. 2011;286:26603–15.CrossRefPubMedPubMedCentral Wang Y, Wang Y, Xu Y, Tong W, Pan T, et al. Hepatitis C virus NS5B protein delays s phase progression in human hepatocyte-derived cells by relocalizing cyclin-dependent kinase 2-interacting protein (CINP). J Biol Chem. 2011;286:26603–15.CrossRefPubMedPubMedCentral
14.
go back to reference Shawki SM, Meshaal SS, El Dash AS, Zayed NA, Hanna MO. Increased DNA damage in hepatitis C virus-related hepatocellular carcinoma. DNA Cell Biol. 2014;33:884–90.CrossRefPubMed Shawki SM, Meshaal SS, El Dash AS, Zayed NA, Hanna MO. Increased DNA damage in hepatitis C virus-related hepatocellular carcinoma. DNA Cell Biol. 2014;33:884–90.CrossRefPubMed
15.
go back to reference Hoare M, Shankar A, Shah M, Rushbrook S, Gelson W, et al. Gamma-H2AX+CD8+ T lymphocytes cannot respond to IFN-alpha, IL-2 or IL-6 in chronic hepatitis C virus infection. J Hepatol. 2013;58:868–74.CrossRefPubMedPubMedCentral Hoare M, Shankar A, Shah M, Rushbrook S, Gelson W, et al. Gamma-H2AX+CD8+ T lymphocytes cannot respond to IFN-alpha, IL-2 or IL-6 in chronic hepatitis C virus infection. J Hepatol. 2013;58:868–74.CrossRefPubMedPubMedCentral
16.
go back to reference Sun H, Gong S, Carmody RJ, Hilliard A, Li L, et al. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell. 2008;133:415–26.CrossRefPubMedPubMedCentral Sun H, Gong S, Carmody RJ, Hilliard A, Li L, et al. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell. 2008;133:415–26.CrossRefPubMedPubMedCentral
17.
go back to reference Zhang X, Wang J, Fan C, Li H, Sun H, et al. Crystal structure of TIPE2 provides insights into immune homeostasis. Nat Struct Mol Biol. 2009;16:89–90.CrossRefPubMed Zhang X, Wang J, Fan C, Li H, Sun H, et al. Crystal structure of TIPE2 provides insights into immune homeostasis. Nat Struct Mol Biol. 2009;16:89–90.CrossRefPubMed
18.
19.
go back to reference Li Y, Li X, Liu G, Sun R, Wang L, et al. Downregulated TIPE2 is associated with poor prognosis and promotes cell proliferation in non-small cell lung cancer. Biochem Biophys Res Commun. 2015;30:43–9. Li Y, Li X, Liu G, Sun R, Wang L, et al. Downregulated TIPE2 is associated with poor prognosis and promotes cell proliferation in non-small cell lung cancer. Biochem Biophys Res Commun. 2015;30:43–9.
20.
go back to reference Zhang YH, Yan HQ, Wang F, Wang YY, Jiang YN, et al. TIPE2 inhibits TNF-alpha-induced hepatocellular carcinoma cell metastasis via Erk1/2 downregulation and NF-kappaB activation. Int J Oncol. 2015;46:254–64.PubMed Zhang YH, Yan HQ, Wang F, Wang YY, Jiang YN, et al. TIPE2 inhibits TNF-alpha-induced hepatocellular carcinoma cell metastasis via Erk1/2 downregulation and NF-kappaB activation. Int J Oncol. 2015;46:254–64.PubMed
21.
go back to reference Xi W, Hu Y, Liu Y, Zhang J, Wang L, et al. Roles of TIPE2 in hepatitis B virus-induced hepatic inflammation in humans and mice. Mol Immunol. 2011;48:1203–8.CrossRefPubMed Xi W, Hu Y, Liu Y, Zhang J, Wang L, et al. Roles of TIPE2 in hepatitis B virus-induced hepatic inflammation in humans and mice. Mol Immunol. 2011;48:1203–8.CrossRefPubMed
22.
go back to reference Wang Z, Fayngerts S, Wang P, Sun H, Johnson DS, et al. TIPE2 protein serves as a negative regulator of phagocytosis and oxidative burst during infection. Proc Natl Acad Sci U S A. 2012;109:15413–8.CrossRefPubMedPubMedCentral Wang Z, Fayngerts S, Wang P, Sun H, Johnson DS, et al. TIPE2 protein serves as a negative regulator of phagocytosis and oxidative burst during infection. Proc Natl Acad Sci U S A. 2012;109:15413–8.CrossRefPubMedPubMedCentral
23.
go back to reference Zhang W, Zhang J, Zhao L, Shao J, Cui J, et al. TIPE2 protein negatively regulates HBV-specific CD8(+) T lymphocyte functions in humans. Mol Immunol. 2015;64:204–9.CrossRefPubMed Zhang W, Zhang J, Zhao L, Shao J, Cui J, et al. TIPE2 protein negatively regulates HBV-specific CD8(+) T lymphocyte functions in humans. Mol Immunol. 2015;64:204–9.CrossRefPubMed
24.
go back to reference Higgs MR, Chouteau P, Lerat H. ‘Liver let die’: oxidative DNA damage and hepatotropic viruses. J Gen Virol. 2014;95:991–1004.CrossRefPubMed Higgs MR, Chouteau P, Lerat H. ‘Liver let die’: oxidative DNA damage and hepatotropic viruses. J Gen Virol. 2014;95:991–1004.CrossRefPubMed
25.
go back to reference Wang AG, Lee DS, Moon HB, Kim JM, Cho KH, et al. Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice. J Pathol. 2009;219:253–62.CrossRefPubMed Wang AG, Lee DS, Moon HB, Kim JM, Cho KH, et al. Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice. J Pathol. 2009;219:253–62.CrossRefPubMed
26.
go back to reference Cheng D, Zhang L, Yang G, Zhao L, Peng F, et al. Hepatitis C virus NS5A drives a PTEN-PI3K/Akt feedback loop to support cell survival. Liver Int. 2015;35:1682–91.CrossRefPubMed Cheng D, Zhang L, Yang G, Zhao L, Peng F, et al. Hepatitis C virus NS5A drives a PTEN-PI3K/Akt feedback loop to support cell survival. Liver Int. 2015;35:1682–91.CrossRefPubMed
27.
go back to reference Cheng D, Zhao L, Zhang L, Jiang Y, Tian Y, et al. p53 controls hepatitis C virus non-structural protein 5A-mediated downregulation of GADD45alpha expression via the NF-kappaB and PI3K-Akt pathways. J Gen Virol. 2013;94:326–35.CrossRefPubMedPubMedCentral Cheng D, Zhao L, Zhang L, Jiang Y, Tian Y, et al. p53 controls hepatitis C virus non-structural protein 5A-mediated downregulation of GADD45alpha expression via the NF-kappaB and PI3K-Akt pathways. J Gen Virol. 2013;94:326–35.CrossRefPubMedPubMedCentral
28.
go back to reference Gimenez-Barcons M, Wang C, Chen M, Sanchez-Tapias JM, Saiz JC, et al. The oncogenic potential of hepatitis C virus NS5A sequence variants is associated with PKR regulation. J Interf Cytokine Res. 2005;25:152–64.CrossRef Gimenez-Barcons M, Wang C, Chen M, Sanchez-Tapias JM, Saiz JC, et al. The oncogenic potential of hepatitis C virus NS5A sequence variants is associated with PKR regulation. J Interf Cytokine Res. 2005;25:152–64.CrossRef
29.
go back to reference Bopp A, Wartlick F, Henninger C, Kaina B, Fritz G. Rac1 modulates acute and subacute genotoxin-induced hepatic stress responses, fibrosis and liver aging. Cell Death Dis. 2013;4:e558.CrossRefPubMedPubMedCentral Bopp A, Wartlick F, Henninger C, Kaina B, Fritz G. Rac1 modulates acute and subacute genotoxin-induced hepatic stress responses, fibrosis and liver aging. Cell Death Dis. 2013;4:e558.CrossRefPubMedPubMedCentral
30.
go back to reference Wartlick F, Bopp A, Henninger C, Fritz G. DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac. Biochim Biophys Acta. 2013;1833:3093–103.CrossRefPubMed Wartlick F, Bopp A, Henninger C, Fritz G. DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac. Biochim Biophys Acta. 2013;1833:3093–103.CrossRefPubMed
Metadata
Title
Hepatitis C virus promotes hepatocellular carcinogenesis by targeting TIPE2, a new regulator of DNA damage response
Authors
Yaohui Wang
Yinan Jiang
Jinxue Zhou
Wuhui Song
Jing Li
Mingli Wang
Jiuge Chen
Rui Xu
Jingjing Zhang
Fanni Ma
Youhai H. Chen
Yuanfang Ma
Publication date
01-11-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5409-z

Other articles of this Issue 11/2016

Tumor Biology 11/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine